Will Morgan Stanley's NVO Downgrade Deepen Patent and Rival Woes?
Novo faces a tougher growth outlook as Morgan Stanley downgrades the stock to Underweight, citing muted growth, patent risks and rising pressure from Lilly.
NVO - Novo Nordisk A/S
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$44.67
DETAILS
HIGH:
$47.00
LOW:
$40.00
MEDIAN:
$47.00
CONSENSUS:
$44.67
UPSIDE:
3.41%
Stock News
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novo Nordisk rebrands as 'Novo', announces cultural reset
Novo Nordisk is changing its day-to-day name to 'Novo', and taking a new approach to company culture as it looks to claw back ground in the fierce obesity drug race, the Danish drugmaker said on Monday.
Novo drops ‘Nordisk' in corporate refresh to take on Lilly in the weight-loss wars
The Danish drug giant behind Ozempic is competing with Eli Lilly in the market for weight-loss drugs.
Novo Nordisk to Rebrand as Novo
The drugmaker said its new name aims to make it more recognizable to compete in the market for obesity medications.
Novo Nordisk rebrands to 'Novo,' unveils corporate changes as it fights for obesity market share
Novo Nordisk said it is rebranding its name to "Novo" and updating its corporate culture, as the company works to win back market share in the obesity drug space. The Danish drugmaker called the changes the beginning of a new chapter, as it faces stiff competition from Eli Lilly and investor pressure to deliver new blockbuster products.
Novo Nordisk May Be Poised to Outpace Eli Lilly With This Key Catalyst
Novo Nordisk launched its Wegovy pill in early 2026, with Eli Lilly quickly following with a pill called Foundayo. Novo Nordisk's pill has been very well received, while Eli Lilly's pill has been slower to gain traction.
Could This New Opportunity Be Worth Billions for Novo Nordisk?
A recent clinical trial win could help Novo Nordisk expand its GLP-1 addressable market. The company is looking to bounce back after multiple setbacks.
Friday's First Moves: RH & KR Earnings Mixed, NVO Downgrade
From high-end furniture to well-known grocery stores, Diane King Hall discusses what RH (RH) and Kroger (KR) earnings say about all income brackets of American consumers. As she explains, both reports showed some weakness in guidance.
This Novo Nordisk Analyst Turns Bearish; Here Are Top 4 Downgrades For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Here Are Friday’s Top Wall Street Analyst Research Calls: Atmos Energy, Celanese, Check Point Software, Chewy, Dell Technologies, Fortinet, Global Payments, HP, Shopify, and More
Markets are bracing for Friday's CPI data after a brutal week of selling across stocks, bonds, and crypto, and Wall Street analysts are already reshuffling their ratings on names like Dell, Shopify, Novo Nordisk, and Fortinet before the dust settles.
Novo Nordisk (NVO) Suffers a Larger Drop Than the General Market: Key Insights
Novo Nordisk (NVO) closed the most recent trading day at $44.01, moving 1.23% from the previous trading session.
Novo Nordisk: Valuation Reflects High Risk, But Solid Margin Of Safety
Novo Nordisk remains a Strong Buy after a robust Q2, with another guidance boost and strong free cash flow growth. NVO's valuation reflects high risk, yet intrinsic value estimates suggest a significant discount to current market price. GLP-1 market leadership persists, but competitive and regulatory pressures, plus post-LOE strategy execution, are critical forward risks.
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie is successfully transitioning its revenue base toward newer immunology drugs to offset the loss of patent protection for Humira. Novo Nordisk maintains a dominant position in the rapidly expanding global markets for diabetes and obesity treatments.
Novo Nordisk says Wegovy approved in China for liver disease MASH
Denmark's Novo Nordisk said on Thursday its blockbuster weight-loss drug Wegovy had been approved in China as the first GLP-1 RA class of drugs for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
2 Beaten-Down Stocks to Avoid Right Now
Don't catch a falling knife.
Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore?
Novo Nordisk was first to market with a GLP-1 weight-loss drug, but lost the lead to Eli Lilly. Novo Nordisk has been working hard to regain lost market share in the GLP-1 space.
Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study
NVO's semaglutide cuts BMI in children with obesity in phase III study, with 40.4% no longer classified as having obesity after 68 weeks.
3 of the Best Growth Stocks to Buy for Less Than $100 Right Now
Netflix, Uber, and Novo Nordisk are all excellent, undervalued stocks to buy today.
Lilly vs. J&J: Betting on Breakout Growth or Built-In Stability?
Lilly and J&J offer distinct paths for investors, with strong growth, expanding pipelines and key headwinds shaping their outlooks.
Price Targets
Morgan Stanley Downgrades Novo Nordisk (NVO) to Underweight
$40.00
(was $44.01)
Thibault Boutherin
·
Morgan Stanley
Berenberg Downgrades Novo Nordisk (NVO) to Hold
$47.00
(was $47.17)
Kerry Holford
·
Berenberg Bank
Novo Nordisk price target raised to $47 from $45 at BMO Capital
$47.00
(was $44.51)
Evan Seigerman
·
BMO Capital
Novo Nordisk price target lowered to $45 from $57 at BMO Capital
$45.00
(was $47.19)
BMO Capital
Novo Nordisk (NVO) PT Raised to $57 at BMO Capital
$57.00
(was $63.80)
Evan Seigerman
·
BMO Capital
Novo Nordisk price target raised to $54 from $47 at HSBC
$54.00
(was $46.36)
HSBC
Novo Nordisk price target lowered to $42 from $43 at Morgan Stanley
$42.00
(was $47.43)
Thibault Boutherin
·
Morgan Stanley
Novo Nordisk (NVO) PT Lowered to $46 at BMO Capital
$46.00
(was $44.97)
Evan Seigerman
·
BMO Capital
Novo Nordisk price target raised to $55 from $50 at BMO Capital
$55.00
(was $57.50)
Evan Seigerman
·
BMO Capital
Novo Nordisk upgraded to Buy from Hold at HSBC
$70.00
(was $59.17)
HSBC
Novo Nordisk downgraded to Underweight from Equal Weight at Morgan Stanley
$47.00
(was $55.61)
Morgan Stanley
Novo Nordisk downgraded to Hold from Buy at HSBC
$57.00
(was $48.88)
HSBC
What's Going On With Hims & Hers Stock Wednesday?
$48.00
(was $70.03)
Jailendra Singh
·
Truist Financial
Novo Nordisk price target lowered to $156 from $160 at BMO Capital
$156.00
(was $118.58)
Evan Seigerman
·
BMO Capital
Cantor Fitzgerald on Novo Nordisk (NVO): 'These data compare favorably to other orals in development'
$160.00
(was $135.23)
Louise Chen
·
Cantor Fitzgerald
Novo Nordisk (NVO) PT Lowered to $160 at BMO Capital
$160.00
(was $126.17)
Evan David Seigerman
·
BMO Capital
Novo Nordisk price target raised to $160 from $125 at Argus
$160.00
(was $142.88)
Jasper Hellweg
·
Argus Research
Novo Nordisk initiated with a Buy at Goldman Sachs
$156.00
(was $132.68)
James Quigley
·
Goldman Sachs
BMO Capital Starts Novo Nordisk (NVO) at Outperform
$163.00
(was $125.40)
Evan David Seigerman
·
BMO Capital